JOHNSON JOHN sold 2.1% of their position (15K shares) of XERIS BIOPHARMA HOLDINGS, INC. on the open market
Open‑market sale worth $91.4K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/5/2026ACC: 0001410781-26-000004
Director
Since Oct 2021
+42.19K
Net shares
Net buyer
$91.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
57.19K acquired · 15K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−15K
Price / share
$6.09
Trade value
$91.42K
% of position
2.1%
6/4/2026
698.08K→683.08K
Common Stock
Direct
Shares
+24.19K
Price / share
—
Trade value
—
% of position
3.5%
6/4/2026
683.08K→707.28K
Total
Net shares
+9.19K
Net value
-$91.42K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/4/2026 | S · Sale | −15K | $6.09 | $91.42K | 2.1% | 698.08K | 683.08K |
| Common Stock Direct | 6/4/2026 | A · Award | +24.19K | — | — | 3.5% | 683.08K | 707.28K |
| Total | +9.19K | -$91.42K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
33K shares
Shares
+33K
Strike price
6.15
Held after
33K
Exercisable
—
6/4/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock33K shares | 6/4/2026 | A · Award | +33K | 6.15 | — | 33K |